Public concern with the upcoming pricing decision for Eisai Co., Ltd. and Biogen, Inc.’s potential Alzheimer’s drug, lecanemab, has been heightened by two new reports covering pricing for such drugs – a House oversight report on Aduhelm and a draft cost effectiveness report from the Institute for Clinical and Economic Review on lecanemab.
Released 29 December, the House report is the product of an 18-month investigation by the Oversight and Investigation and...







